New Kidney360 Publication Highlights CareDx’s AlloSure is Differentiated as the dd-cfDNA Test of Choice

Rhea-AI Summary

CareDx, Inc. (Nasdaq: CDNA) announced the publication of a study in Kidney360 evaluating its AlloSure tool against another monitoring method for kidney transplant rejection. The study, involving 76 patients, indicated that AlloSure provides faster results, with 75% of results delivered at least one day earlier than its counterpart, demonstrating superior accuracy in clinical interpretation. This validation highlights AlloSure's effectiveness in addressing transplant-specific testing needs.

Positive

• AlloSure demonstrated faster turnaround times, with 75% of results returned at least one day earlier compared to another dd-cfDNA tool.
• The study reaffirms AlloSure's accuracy in clinical interpretation for kidney transplant rejection.

Negative

• None.

SOUTH SAN FRANCISCO, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announces today that the journal of the American Society of Nephrology, Kidney360, published a study evaluating AlloSure simultaneously with a different donor-derived cell-free DNA (dd-cfDNA) monitoring tool for allograft rejection.

This study evaluated 76 kidney transplant patients and surveilled post-transplant kidney rejection utilizing AlloSure and one other dd-cfDNA monitoring tool. Overall, the study found that while there were no significant differences between the diagnostic test characteristics, AlloSure was proven to be more accurate in clinical interpretation and significantly faster in delivering patient results. The study evaluated dd-cfDNA samples and concluded that AlloSure had a significantly superior turnaround time with 75% of the results returned at least one day earlier.

“Our study findings further validated the published data on AlloSure, a transplant-focused analytical tool for allograft rejection using donor-derived cell-free DNA,” said Joseph K. Melancon, MD, The George Washington University Hospital. “Although dd-cfDNA tests are similar, they are not the same.”

“While CareDx was not involved in this head-to-head comparison, we are not surprised by the results as AlloSure was developed for transplant specific needs, including accurate testing at low cfDNA levels and fast turnaround times,” said Sham Dholakia, SVP of Medical Affairs at CareDx.

About CareDx
CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey, and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.

CONTACTS:

CareDx, Inc.
Sasha King
Chief Marketing Officer
415-287-2393
sking@caredx.com

Investor Relations
Greg Chodaczek
646-924-1769
investor@caredx.com 

FAQ

What did the study published in Kidney360 reveal about CareDx's AlloSure?

The study found that AlloSure provided faster results and greater accuracy in clinical interpretation compared to another dd-cfDNA monitoring tool.

How many patients were involved in the AlloSure study?

The study evaluated 76 kidney transplant patients.

What is the significance of the AlloSure test's turnaround time?

AlloSure returned 75% of results at least one day earlier, indicating a quicker response for monitoring kidney transplant rejection.

Is CareDx involved in the study comparing AlloSure with other monitoring tools?

CareDx was not involved in the head-to-head comparison, but expressed confidence in the results due to AlloSure's design for transplant-specific needs.

What does the study say about donor-derived cell-free DNA tests?

The study confirmed that while dd-cfDNA tests show similarities, they are not the same, emphasizing AlloSure’s advantages.